Revista de Ensino, Ciência e Inovação em Saúde v.2, n. 2 (2021) 39-43 ISSN: 2675-9683/DOI: 10.51909/recis.v2i2.61 39 Noschang J, et. al / Revista de Ensino, Ciência e Inovação em Saúde v.2 n.2(2021) p. 39-43 Lung-RADS used in Lung Cancer Screening: Does granulomatous disease make a difference in a developing country? Lung-RADS usado no rastreamento do câncer de pulmão: a doença granulomatosa faz diferença em um país em desenvolvimento? Julia Noschang¹, Karen Cristina Barbosa Chaves², Fabio José Haddad¹, Paula Nicole Vieira Pinto Barbosa¹, Almir Galvão Vieira Bitencourt¹, Ricardo Sales Santos³, Jefferson Luiz Gross¹, Cleusa Wanderley de Queiroz Andrade 5 , Carine Rosa Naue 5 , Marcos Duarte Guimarães 1,5 1 A.C. Camargo Cancer Center, São Paulo, Brazil, 2 Universidade de São Caetano do Sul, São Paulo, Brazil, 3 Hospital Israelita Albert Einstein, São Paulo, Brazil, 4 Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil, 5 Universidade Federal do Vale do São Francisco, Petrolina, Brazil Corresponding author: marcosduarte500@gmail.com Artigo recebido em 17/03/2021 e aceito em 11/06/2021 ___________________________________________________________________ ABSTRACT To analyze the outcomes of low-dose computed tomography (LDCT) lung cancer screening using Lung CT Screening Reporting and Data System (Lung-RADS) in a cancer center located at an endemic granulomatous disease region. Retrospectively reviewed the medical records of patients submitted to baseline LDCT lung cancer screening program at a Brazilian cancer center. The eligibility criteria were the same as those for the National Lung Cancer Screening Trial (NLST). The criteria for image findings were those classified according to Lung Imaging Reporting and Data System (Lung-RADS) assessment categories. From May 2017 to April 2018, 552 individuals submitted to baseline LCDT lung cancer screening program, 265 of these were not eligible and 287 were matched. The mean age of 61.7 years (SD, 5.4), the proportion of current smokers was 99.6% (286 participants) with a mean of 45.3 pack-year (SD, 17.8). Negative LDCT scans were reported in 207 (72.1%) patients. Positive LDCT scans were reported in 80 (27.9%) individuals classified Lung-RADS category 3 (19.1%), 4A (5.6%), 4B (2.1%) or 4X (1.0%). In 9 cases had a CT follow-up, 7 of these had stable nodules and 2 had nodules increased. In 4 cases, were indicated percutaneous biopsy and half of these were confirmed as lung cancer. Despite the higher prevalence of lesions on categories 3 and 4A, the use of Lung-RADS allowed to stratify the findings and standardize management decisions in LDCT screening for lung cancer, which corresponds to 0.7% of prevalence in the present study, in areas of endemic granulomatous disease. Keywords: Lung neoplasms; Early detection of cancer; Tomography scanners. RESUMO Analizar o rastreamento de câncer de pulmão por tomografia computadorizada de baixa dose (TCBD) utilizando o sistema Lung Imaging Reporting and Data System (Lung-RADS) em um centro de câncer localizado em uma região endêmica para doença granulomatosa. Foram analisados retrospectivamente os prontuários de pacientes submetidos ao programa de rastreamento de câncer de pulmão por TCBD em um centro de câncer brasileiro. Os critérios de elegibilidade foram iguais aos do National Lung Cancer Screening Trial (NLST). Os critérios para achados de imagem foram classificados de acordo com as categorias de avaliação do Lung-RADS. De maio de 2017 a abril de 2018, 552 indivíduos foram submetidos ao programa, sendo 265 deles não elegíveis e 287 elegíveis. A idade média foi de 61,7 anos (DP, 5,4), a